CASI Pharmaceuticals, Inc. (CASI)

Market Cap	74.47M
Revenue (ttm)	42.26M
Net Income (ttm)	-40.42M
Shares Out	13.32M
EPS (ttm)	-3.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,379
Open	5.56
Previous Close	5.59
Day's Range	5.38 - 5.72
52-Week Range	1.45 - 5.94
Beta	0.16
Analysts	Strong Buy
Price Target	12.00 (+114.67%)
Earnings Date	Nov 14, 2023

About CASI

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc"RIIB ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 11, 1996
• Employees: 224
• Stock Exchange: NASDAQ
• Ticker Symbol: CASI

Financial Performance

In 2022, CASI's revenue was $43.11 million, an increase of 42.89% compared to the previous year's $30.17 million. Losses were -$41.01 million, 11.9% more than in 2021.

Analyst Forecast

According to one analyst, the rating for CASI stock is "Strong Buy" and the 12-month stock price forecast is $12.0.

Price Target

$12.0

(114.67% upside)

Analyst Consensus: Strong Buy